Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET
Company Participants
Tram Bui - Vice President, Investor Relations and Corporate Communications
Helen Torley - President and Chief Executive Officer
Nicole LaBrosse - Chief Financial Officer
Conference Call Participants
Na Sun - JPMorgan
Corinne Jenkins - Goldman Sachs
Mohit Bansal - Wells Fargo
Michael DiFiore - Evercore ISI
Roy Buchanan - JMP Securities
David Risinger - SVB Securities
Caroline Palomeque - Berenberg Capital Markets
Operator
Good afternoon, my name is Chris and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Halozyme First Quarter 2023 Financial and Operating Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. [Operator Instructions] Please note this event is being recorded.
I'll now turn the call over to Tram Bui, Halozyme's Vice President of Investor Relations and Corporate Communications. Please go ahead.
Tram Bui
Thank you, operator. Good afternoon and welcome to our First Quarter 2023 Financial and Operating Results Conference Call. In addition to the press release issued today after the market close, you can find a supplementary slide presentation that will be referenced during today's call in the Investor Relations section of our website.
Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer who will provide an update on our business and Nicole LaBrosse, our Chief Financial Officer will review our financial results for the first quarter 2023.
On today's call, we will be making forward-looking statements as outlined on slide two. I would also refer you to our SEC filings for a full list of risks and uncertainties. During the call, both GAAP and non-GAAP financial measures will be discussed. Certain non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in our earnings press release and slide presentation.
I will now turn the call over to Helen Torley.
Helen Torley
Thank you, Tram, and good afternoon, everyone. Let me begin on slide three. Halozyme is a leading drug delivery platform company with a diversified and robust business, which include our ENHANZE royalty business, our auto injector technology business and a specialty commercial portfolio.
I'm pleased to report that we executed our plan for the first quarter of 2023 achieving total revenue of $162 million, a 38% increase year-over-year. This performance sets us up well for the year and we expect strong quarter-over-quarter revenue growth throughout 2023 that will result in another record revenue year.